OCGN Stock Chart & Stats
$25.00
-$0.93(-4.15%)
At close: 4:00 PM EDT
$25.00
-$0.93(-4.15%)
Day’s Range― - ―
52-Week Range$14.44 - $45.50
Previous CloseN/A
Volume141.00
Average Volume (3M)144.00
Market Cap
$7.62B
Enterprise Value$506.12
Total Cash (Recent Filing)$100.05M
Total Debt (Recent Filing)$87.99M
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Nov 10, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding339,110,400
10 Day Avg. Volume0
30 Day Avg. Volume144
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$171.05Price Target Upside584.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.28
Revenue Forecast (FY)$80.68M
Bulls Say, Bears Say
Bulls Say
Late-stage Regulatory ProgressFDA clearance and RMAT designation reduce a major development hurdle for OCU410 and establish a registrational path in geographic atrophy. If execution remains on schedule, this could accelerate clinical validation and support a potential BLA, strengthening Ocugen’s late-stage pipeline position.
Clinical Efficacy And Safety SignalsMeaningful Phase II efficacy signals alongside the absence of drug-related serious adverse events provide important support for continued development of OCU410. A differentiated efficacy and safety profile could improve the candidate’s competitive position and increase the likelihood of successful late-stage execution.
Funding And Manufacturing ReadinessThe financing provides resources to advance three late-stage programs through key clinical and regulatory milestones, reducing near-term funding pressure. Completed process-performance qualification batches also indicate progress toward reliable commercial supply if OCU400 receives approval.
Bears Say
Negative Equity And Rising DebtNegative equity combined with sharply higher debt weakens financial flexibility and increases dependence on external funding. This capital structure can raise refinancing and dilution risk while limiting the company’s ability to absorb clinical delays, regulatory setbacks, or higher development costs.
Persistent Cash BurnThe company is not yet self-funding its operations, with substantial operating and free-cash-flow deficits continuing alongside clinical investment. Sustained cash consumption means available financing must support development, and any delay in partnerships or approvals could increase future capital requirements.
Commercial And Reimbursement UncertaintyEven successful clinical development may not translate quickly into durable revenue because reimbursement, pricing, treatment pathways, and provider infrastructure remain unresolved. These issues could slow adoption, affect achievable economics, and make commercialization outcomes less predictable across the pipeline.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $14.44 and its highest was $45.50 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $7.62B.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 10, 2026 which is in 61 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 06, 2026. The company reported -$1.183 earnings per share for the quarter, missing the consensus estimate of -$0.895 by -$0.287.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -1.01.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 339,110,400 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$1.183 in its last earnings report, missing expectations of -$0.895. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in MX:OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$171.05 (584.21% Upside)
$171.05 (584.21% Upside)
Blogger Sentiment
Bullish
MX:OCGN Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $436.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
131.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.View all MX:OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$171.05
▲(584.21% Upside)